Boost radiation for intermediate or higher-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a stronger, focused radiation plan for intermediate to higher-risk prostate cancer. It combines a high-dose internal radiation “boost” with external radiation to try to improve cancer control while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven prostate cancer that is intermediate or higher risk
- You have not had any prior “definitive” prostate cancer treatment
- Scans show no spread to lymph nodes or bones (CT/MRI/PSMA PET, and a bone scan or PSMA PET)
- Your predicted risk is high enough (at least 15% chance of lymph node involvement by a prostate surgery risk tool)
- You can have HDR brachytherapy (your care team says it’s a good option for you)
- Your urine symptoms are not too severe (AUA score below 15)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding a targeted “boost” of HDR (high-dose-rate) internal radiation to the prostate along with standard external beam radiation. It may help improve cancer control while keeping the treatment focused on the area seen on scans and biopsy.
This trial studies a specific radiation schedule for prostate cancer (with an extra “boost” dose) and checks whether it works well and is tolerable. It may help people with higher-risk, localized prostate cancer by aiming at the cancer while limiting side effects to surrounding tissues.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.